RNLXY Renalytix plc
Services-Medical Laboratories · OTC · SEC CIK 1811115 · Fiscal year ends 06/30
Financial factors as of 2024-03-31 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-40.2%
TTM net income YoY5.5%
TTM EPS YoY30.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-1.6%
Operating margin-1,531.6%
Net margin-1,687.8%
FCF margin—
EBITDA margin-1,515.1%
Returns
ROE-1,073.2%
ROA-154.4%
ROIC (approx.)—
Asset turnover0.09x
Leverage & solvency
Liabilities / assets226.7%
Debt / equity—
Current ratio0.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-27.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 | FY20212021-06-30 | FY20202020-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.29M | $3.40M | $2.97M | $1.49M | $0 |
| Cost of revenue | $2.13M | $2.68M | $2.10M | $858,000 | $0 |
| Gross profit | $156,000 | $720,000 | $874,000 | $633,000 | $0 |
| R&D expense | $9.29M | $14.30M | $14.65M | $10.04M | $4.57M |
| SG&A expense | $19.75M | $28.66M | $39.52M | $23.48M | $5.75M |
| Operating income | -$29.61M | -$42.22M | -$53.18M | -$31.92M | -$10.31M |
| Pretax income | -$33.45M | -$45.60M | -$45.25M | -$35.34M | -$9.84M |
| Income tax | $4,000 | $2,000 | $25,000 | $0 | $0 |
| Net income | -$33.46M | -$45.61M | -$45.28M | -$35.34M | -$9.84M |
| EBITDA | -$29.24M | -$41.71M | -$52.69M | -$31.63M | -$10.24M |
| EPS (basic) | -0.31 | -0.55 | -0.62 | -0.49 | -0.17 |
| EPS (diluted) | -0.31 | -0.55 | -0.67 | -0.49 | -0.17 |
| Weighted avg. shares (diluted) | 108.18M | 82.21M | 73.84M | 71.48M | 59.08M |
| Balance sheet | |||||
| Cash & equivalents | $4.68M | $24.68M | $41.33M | $65.13M | $13.29M |
| Short-term investments | — | — | — | $0 | $982,000 |
| Receivables | $722,000 | $776,000 | $901,000 | $594,000 | — |
| Current assets | $6.12M | $26.88M | $44.75M | $66.79M | $14.84M |
| PP&E, net | $216,000 | $1.03M | $1.37M | $2.49M | $1.66M |
| Intangibles | $869,000 | $1.05M | $1.19M | $1.23M | — |
| Total assets | $7.97M | $30.63M | $50.06M | $78.58M | $20.88M |
| Current liabilities | $11.49M | $16.14M | $11.78M | $7.06M | $3.29M |
| Total liabilities | $15.83M | $23.66M | $19.46M | $7.12M | $4.97M |
| Shareholders' equity | -$7.85M | $6.97M | $30.61M | $71.46M | $15.91M |
| Shares outstanding | 154.37M | 93.78M | 74.76M | 72.20M | 59.42M |
| Cash flow statement | |||||
| Operating cash flow | -$30.11M | -$34.09M | -$45.92M | -$28.40M | -$9.52M |
| Capital expenditure | — | $0 | $557,000 | $773,000 | $804,000 |
| Free cash flow | — | -$34.09M | -$46.48M | -$29.17M | -$10.33M |
| Investing cash flow | -$4,000 | $0 | -$662,000 | -$751,000 | -$1.17M |
| Financing cash flow | $10.25M | $16.39M | $25.63M | $77.24M | $15.94M |
| Depreciation & amortization | $364,000 | $508,000 | $489,000 | $282,000 | $70,000 |
| Stock-based compensation | $1.71M | $2.93M | $4.62M | $2.66M | $1.16M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.